Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ASCO Highlights

Written by | 20 Aug 2018

June 2018 saw the launch of our first edition of LungCancer.Med, a new congress news e-journal containing interviews with speakers and delegates as well as articles on the latest hot… read more.

EHA 2018: Immunotherapy in MM: why, when and how?

Written by | 24 Jun 2018

The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.

BSH 2018: Personalised cancer vaccines and cellular therapy: changing the treatment paradigm for haematological malignancies

Written by | 11 May 2018

Dendritic cells (DC) are known to play an important role in the initiation of primary immune responses. In cancer, deficient DCs contribute to tumour-associated immune tolerance. Functionally active… read more.

Mixed results for new NHL therapies

Written by | 15 Jan 2018

Professor Stephen Ansell (Mayo Clinic, USA) speaks about harnessing the power of immunotherapy in Non Hodgkin’s Lymphoma.

ICML 2017: Response-adapted therapy for Hodgkin’s lymphoma

Written by | 30 Sep 2017

Professor Peter Johnson (Southampton, UK) tells us what’s new with response-adapted therapy and what are the benefits to patients.

ICML 2017: The role of stem cell transplantation for lymphoma in 2017

Written by | 11 Jul 2017

By Maria Dalby (article) and Esther Drain (interviews) Even in an era of rapid progress in terms of new agents and treatment approaches, stem cell transplantation (SCT) continues… read more.

ESH ICMM Highlights

Written by | 3 Oct 2016

Professor Mohamad Mohty (Paris), Professor Sagar Lonial  (Atlanta) and Dr Karthik Ramasamy (Oxford) discuss their highlights from The European School of Haematology Congress on Multiple Myeloma this month. This issue covers the growing… read more.

ASCO 2016: Previously untreatable advanced bladder cancer patients respond to immunotherapy

Written by | 4 Jul 2016

by Bruce Sylvester: Anti-PD-L1 immunotherapy atezolizumab (TECENTRIQ) has shown efficacy in previously untreated patients with advanced bladder cancer who are ineligible for standard treatment with cisplatin.

ISH/BSH 2016: Changing treatment paradigms in multiple relapse HL

Written by | 8 Jun 2016

Professor Karl Peggs, University College, London. by Christine Clark: There are numerous regimens for salvage treatment of Hodgkin lymphoma and all are associated with an overall response rate… read more.

EMA Highlights: New options for melanoma patients with poor prognosis

Written by | 29 Jun 2015

by Gary Finnegan: Keytruda (pembrolizumab) has been recommended by the European Medicines Agency (EMA) as monotherapy for the treatment of adult patients with advanced melanoma that cannot be… read more.

EMA Highlights: Green light for rare cancer treatments

Written by | 25 Jun 2015

by Gary Finnegan: Survival rates in young patients with high-risk neuroblastoma can be improved by Unituxin (dinutuximab), a new treatment approved by the European Medicines Agency (EMA).

ASCO 2015 Report: Dual immunotherapy improves progression-free survival in advanced melanoma

Written by | 10 Jun 2015

by Bruce Sylvester: Treatment of advanced melanoma with a combination of  nivolumab (Opdivo™) and ipilimumab (Yervoy™) or with nivolumab alone increases progression-free survival over ipilimumab monotherapy, researchers reported… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.